Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AURA - Aura Biosciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$17.50
DETAILS
HIGH:
$18.00
LOW:
$17.00
MEDIAN:
$17.50
CONSENSUS:
$17.50
UPSIDE:
186.89%
Stock News
Aura Biosciences, Inc. $AURA Shares Bought by Frazier Life Sciences Management L.P.
Frazier Life Sciences Management L.P. grew its position in shares of Aura Biosciences, Inc. (NASDAQ: AURA) by 39.2% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,100,000 shares of the company's stock after purchasing an additional 2,000,000 shares during the quarter. Aura
Aura Biosciences to Participate in Upcoming Investor Conference
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.
BlackRock Inc. Makes New Investment in Aura Biosciences, Inc. $AURA
BlackRock Inc. bought a new stake in shares of Aura Biosciences, Inc. (NASDAQ: AURA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 4,707,674 shares of the company's stock, valued at approximately $33,424,000. BlackRock Inc. owned approximately 4.55% of
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura's new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura's new Chief Operating Officer, and Julie Person, Aura's new Chief People Officer, each on September 1, 2026 (the “Grant Date”). The Inducement Awards were approved by the Compensation Committee of the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
ADAR1 Capital Management LLC Acquires Shares of 130,152 Aura Biosciences, Inc. $AURA
ADAR1 Capital Management LLC bought a new position in shares of Aura Biosciences, Inc. (NASDAQ: AURA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 130,152 shares of the company's stock, valued at approximately $924,000. ADAR1 Capital Management LLC
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval
Aura Biosciences, Inc. is focused on late-stage development of Bel-sar for early choroidal melanoma, addressing significant unmet medical needs. The Phase 3 CoMpass trial is fully enrolled, with topline data expected in 2H 2027; Phase 2 data showed 80% tumor control and strong safety. A recent C-suite overhaul and $299M capital raise position AURA to prioritize ocular oncology and streamline operations, with funding expected to last into 2029.
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors.
Auranova and Kenorland Announce Large Intrusion-Related Gold Discovery at the South Uchi Project, Ontario
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") and Kenorland Minerals Ltd. ("Kenorland") are pleased to announce complete assay results from the 2026 spring (phase 3) diamond drill program at the South Uchi Project (the "Project"), located in the Red Lake District of Ontario.
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint are anticipated in the second half of 2027.
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
Aura Biosciences NASDAQ: AURA is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal melanoma nears completion, newly appointed CEO Natalie Holles said during a fireside chat at TD Cowen's seventh annual Oncology Innovation Summit.
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences NASDAQ: AURA executives outlined the company's strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company's initial development focus while also discussing ongoing work in non-muscle invasive bladder cancer.
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Natalie Holles, Aura's new Chief Executive Officer and President, on May 19, 2026 (the “Grant Date”). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles' offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on Tuesday, May 19, 2026.
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance sheet with oversubscribed $299 million equity financing; cash position expected to fund operations into 2H 2028 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights. “We are entering a pivotal period for Aura as we advance our Phase 3 CoMpass trial toward enrollment completion and potential registration,” said Natalie Holles, Chief Executive Officer of Aura Biosciences.
AMG Reports Better than Expected First Quarter 2026 Results
Amsterdam, 6 May 2026 (Regulated Information) --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) reports first quarter 2026 adjusted EBITDA of $44 million. This was a 2% improvement compared to the $43 million in the fourth quarter of 2025 and exceeded our guidance that the first quarter 2026 would be down sequentially. This better-than-expected performance in the current quarter was mainly driven by AMG Vanadium which included the consolidation of AURA beginning January 1, 2026. Beyond circular molybdenum, AURA brought recycled tungsten into our critical materials portfolio, and the tungsten price performance helped their results. Despite anticipated lower cash generation at the beginning of the year, AMG ended the quarter with a strong balance sheet highlighted by our $403 million of total liquidity as of March 31, 2026. This figure does not include the $127 million of proceeds from the capital increase.
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the closing of its previously announced underwritten public offering. In the offering, Aura sold (i) 46,099,650 shares of common stock, which includes 6,508,650 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering, and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 3,800,000 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant.
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 39,591,000 shares of its common stock and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 3,800,000 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant. In addition, Aura has granted the underwriters a 30-day option to purchase up to an additional 6,508,650 shares of its common stock on the same terms and conditions. The offering price of each share of common stock is $6.00. The offering price of each pre-funded warrant is $5.99999.
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock.
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Aura intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its common stock (and shares of common stock underlying pre-funded warrants) offered in the public offering on the same terms and conditions. All of the shares of common stock and pre-funded warrants to be sold in the offering will be offered by Aura. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Price Targets
Aura Biosciences price target lowered to $18 from $24 at H.C. Wainwright
$18.00
(was $7.98)
H.C. Wainwright
Aura Biosciences price target lowered to $17 from $26 at Leerink
$17.00
(was $7.90)
Leerink Partners
Aura Biosciences price target lowered to $19 from $21 at Citizens JMP
$19.00
(was $5.99)
Jonathan Wolleben
·
JMP Securities
Aura Biosciences price target raised to $25 from $22 at H.C. Wainwright
$25.00
(was $7.08)
Edward White
·
H.C. Wainwright
Aura Biosciences (AURA) PT Raised to $23 at Scotiabank
$23.00
(was $10.29)
George Farmer
·
Scotiabank
Aura Biosciences (AURA) PT Raised to $22 at H.C. Wainwright
$22.00
(was $10.29)
Ed White II
·
H.C. Wainwright
Aura Biosciences (AURA) PT Raised to $24 at BTIG
$24.00
(was $10.29)
Julian Harrison
·
BTIG
Aura Biosciences initiated with a Buy at H.C. Wainwright
$21.00
(was $9.27)
Edward White
·
H.C. Wainwright
JMP Securities Maintains Market Outperform on Aura Biosciences, Raises Price Target to $30
$30.00
(was $12.95)
JMP Securities